DDrare: Database of Drug Development for Rare Diseases

222. 一次性ネフローゼ症候群
［臨床試験数：234，薬物数：241（DrugBank：78），標的遺伝子数：59，標的パスウェイ数：185］

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 100 mg AP1189; ABATACEPT; ACH-0144471; ACTH; ACTHar; ALXN2040 (ACH-0144471); AP1189; APL-2; AVACOPAN; Abatacept; Acetaminophen; Acetate; Acid mycophenolic (Myfortic); Acthar; Acthar Gel; Adalimumab; Adalimumab (Humira); Adrenocorticotrophic hormone ACTH; Advagraf 0,5mg; Advagraf 1mg; Advagraf 5mg; Aldosterone; Aliskiren; Amoxicillin; Angiotensin; Angiotensin II; Apixaban; Apixaban 5 MG; Aprovel (150 mg); Aprovel 150 mg Tablets; Atorvastatin; Atrasentan; Avacopan; BELIMUMAB; BENLYSTA; BENLYSTA®; BENLYSTA® (belimumab); BMS-188667; Bardoxolone; Bardoxolone methyl; Bardoxolone methyl capsules; Basiliximab; Belimumab; Belimumab 10 mg; Benlysta; Benlysta (belimumab); Bleselumab; CCX140; CCX140-B; CCX168; CDX; CDX-1135; CXA-10; CYCLOPHOSPHAMIDE; Calcium; Chlorambucil; Ciclofosfamida; Ciclosporin; Clarithromycin; Conventional therapy; Corticosteroid; Corticotropin; CsA; CyA; Cyclophosphamide; Cyclophosphamide and steroids; Cyclosporin; Cyclosporin, low dose steroid; Cyclosporine; Cyclosporins; D-Galactose; Dacortín 2,5mg; Dacortín 30mg; Dacortín 5mg; Dalteparin; Danicopan; Danzhu Fuyuan Granule; Dapagliflozin; Daratumumab; Device: LIPOSORBER® LA-15; Device: LIPOSORBER® LA-15 System; Dexamethasone; Diphenhydramine; ECULIZUMAB; ENDOXAN BAXTER*50CPR RIV 50MG; Eculizumab; Eliquis; Enalapril; Endoxan; Evolocumab; Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab); FCM; FG-3019; FK506; Filgotinib; Fluvastatin; Fragmin; Fresolimumab; GC1008; GFB-887; GSK1550188; GSK1550188 (Belimumab); GZ402669; Galactose; Genoxal; Gold; H.P. Acthar Gel; Hydroxychloroquine; INN not available yet; IRBESARTAN; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous injection; Irbesartan; Irbesartan tablets; Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03; Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC; Jianpixiaozhong particles and Wuse Dietotherapy; LA; LNP023; LT4; Lanraplenib; Lansoprazole; Lansoprazole, amoxicillin, clarithromycin; Lisinopril; Lisinopril, losartan, and atorvastatin; Losartan; Losartan Tablets & QingReMoShen Granule; Losmapimod; MABTHERA; MABTHERA*EV 1FL 50ML 500MG; MEDROL*10CPR DIV 4MG; METHYLPREDNISOLONE; MMF; MMF and Dexamethasone; MOR03087; MOR202; MP and CTX; MabThera; MabThera 100 mg concentrate for solution for infusion; MabThera 500 mg concentrate for solution for infusion; Medrol; Mesenchymal stem cells; Methylprednisolone; Methylprednisone; Mizoribine; Mycophenolate; Mycophenolate Mofetil; Mycophenolate Mofetil (MMF); Mycophenolate mofetil; Mycophenolate mofetil orally 1000 mg twice a day (BID); Mycophenolate mofetil, low dose steroid; Mycophenolate sodium; Mycophenolic acid; Mycophenolic sodium; Myfortic; Myfortic 180mg Tablets; Myfortic 360mg Tablets; Myfortic plus low-dose steroid; Narsoplimab; Neoral; OMS721 (narsoplimab); Obinutuzumab; Oral Cyclosporine; Orencia; Other: D5W; Other: Normal Saline; Over-encapsulated 75 mg Irbesartan Tablets; Over-encapsulated Irbesartan Tablets; PF-06730512; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; Pegcetacoplan; Pentoxifylline; Perindopril; Pirfenidone; Ponticelli Regimen; Prednisolone; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisona; Prednisone; Prednisone 0,5 mg/kg orally on alternate days; Prednisone, FK506, MMF; Prednisone, ciclosporin and mycophenolate mofetil; Procedure: Plasma exchange; Procedure: Plasmapheresis; Prograf; Propagermanium; RE-021; RE-021 (Sparsentan); RITUXIMAB; RTX; Repository Corticotropin Injection; Rituximab; Rituximab Infusion; Rosiglitazone; Rosiglitazone (Avandia); SPARSENTAN; Sirolimus; Soliris; Solondo; Sparsentan; Sparsentan/Over-encapsulated Sparsentan tablet; Sparsentan/Over-encapsulated Sparsentan tablets; Steroid & Cyclosporin; Sulfate; Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin); Synacthen Depot; Synacthen Depot 1mg; TACROLIMUS; TRU-015; TRUXIMA; TRUXIMAB; TW; Tacrolimus; Tacrolimus Capsules; Tacrolimus combined with prednisone; Tetracosactide; Tetracosactide hexacetaat; The Comprehensive Treatment Regimen of Traditional Chinese Medicine; The immunosuppressive agents; Tripterygium; Tripterygium Wilfordii; Tripterygium wilfordii; Tripterygium wilfordii (TW); Truxima; URBASON*IM EV 1F 250MG+1F 5ML; Urbason; VB119; VX-147; VX147; Valproic Acid; Valproic acid; Valsartan; Vitamin D; Voclosporin; Zestril; [CCX140-B];  LNP023 HYDROCHLORIDE SALT

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03949855 (ClinicalTrials.gov)	December 18, 2019	13/5/2019	Belimumab With Rituximab for Primary Membranous Nephropathy	Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)	Membranous Nephropathy;MN	Drug: Belimumab;Drug: Placebo for Belimumab;Drug: Rituximab	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN);GlaxoSmithKline	Recruiting	18 Years	75 Years	All	124	Phase 2	United States;Canada
2	NCT01762852 (ClinicalTrials.gov)	April 2013	4/1/2013	Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy	BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy	Glomerulonephritis, Membranous	Drug: Belimumab 10 mg;Drug: Placebo	GlaxoSmithKline	NULL	Withdrawn	18 Years	75 Years	All	0	Phase 2	United States;Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom
3	EUCTR2011-000242-38-CZ (EUCTR)	14/02/2013	13/11/2012	A 2 year study to investigate belimumab in membranous nephropathy	BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - GSK1550188 in membranous nephropathy	Idiopathic Membranous Nephropathy (IMN) MedDRA version: 14.1;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: BENLYSTA ® Product Name: BENLYSTA ® Product Code: GSK1550188 (Belimumab) INN or Proposed INN: BELIMUMAB	GlaxoSmithKline Research & Development Ltd	NULL	Not Recruiting			Female: yes Male: yes	94		United States;France;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;United Kingdom;Italy
4	EUCTR2011-000242-38-DE (EUCTR)	09/01/2013	25/09/2012	A 2 year study to investigate belimumab in membranous nephropathy	BEL114674: A 2 year study of efficacy and safety ofintravenous belimumab versus placebo in subjects withidiopathic membranous nephropathy - GSK1550188 in membranous nephropathy	Idiopathic Membranous Nephropathy (IMN) MedDRA version: 16.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: BENLYSTA ® Product Name: BENLYSTA ® Product Code: GSK1550188 (Belimumab) INN or Proposed INN: BELIMUMAB	GlaxoSmithKline Research & Development Ltd	NULL	Not Recruiting			Female: yes Male: yes	94		France;United States;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;Italy;United Kingdom
5	EUCTR2011-000242-38-ES (EUCTR)	20/12/2012	22/10/2012	A 2 year study to investigate belimumab in membranous nephropathy	A 2 year study of efficacy and safety ofintravenous belimumab versus placebo in subjects withidiopathic membranous nephropathy - GSK1550188 in membranous nephropathy	Idiopathic Membranous Nephropathy (IMN) MedDRA version: 14.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: BENLYSTA ® Product Name: BENLYSTA ® Product Code: GSK1550188 (Belimumab) INN or Proposed INN: BELIMUMAB	GlaxoSmithKline, S.A.	NULL	Not Recruiting			Female: yes Male: yes	94		United States;France;Czech Republic;Canada;Spain;Netherlands;Germany;United Kingdom;Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2011-000242-38-IT (EUCTR)	22/11/2012	11/12/2012	A 2 year study to investigate belimumab in membranous nephropathy	A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy	Idiopathic Membranous Nephropathy (IMN) MedDRA version: 14.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: BENLYSTA INN or Proposed INN: BELIMUMAB	GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.	NULL	Not Recruiting			Female: yes Male: yes	94		United States;Czech Republic;Canada;Spain;Germany;United Kingdom;Italy
7	EUCTR2011-000242-38-GB (EUCTR)	01/11/2012	03/10/2012	A 2 year study to investigate belimumab in membranous nephropathy	BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - GSK1550188 in membranous nephropathy	Idiopathic Membranous Nephropathy (IMN) MedDRA version: 15.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		GlaxoSmithKline Research & Development Ltd	NULL	Not Recruiting			Female: yes Male: yes	94	Phase 2	France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;Italy;United Kingdom
8	EUCTR2012-000385-38-GB (EUCTR)	18/05/2012	02/04/2012	A study to investigate belimumab in IMGN	BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy	Idiopathic Membranous Glomerulonephropathy (IMGN) MedDRA version: 16.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		GlaxoSmithKline Research and Development Ltd	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 2	United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03949855
(ClinicalTrials.gov)

December 18, 2019

13/5/2019

Belimumab With Rituximab for Primary Membranous Nephropathy

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)

Membranous Nephropathy;MN

Drug: Belimumab;Drug: Placebo for Belimumab;Drug: Rituximab

National Institute of Allergy and Infectious Diseases (NIAID)

Immune Tolerance Network (ITN);GlaxoSmithKline

Recruiting

18 Years

75 Years

All

124

Phase 2

United States;Canada

NCT01762852
(ClinicalTrials.gov)

April 2013

4/1/2013

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

Glomerulonephritis, Membranous

Drug: Belimumab 10 mg;Drug: Placebo

GlaxoSmithKline

NULL

Withdrawn

18 Years

75 Years

All

Phase 2

United States;Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom

EUCTR2011-000242-38-CZ
(EUCTR)

14/02/2013

13/11/2012

A 2 year study to investigate belimumab in membranous nephropathy

BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - GSK1550188 in membranous nephropathy

Idiopathic Membranous Nephropathy (IMN)
MedDRA version: 14.1;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: BENLYSTA ®
Product Name: BENLYSTA ®
Product Code: GSK1550188 (Belimumab)
INN or Proposed INN: BELIMUMAB

GlaxoSmithKline Research & Development Ltd

NULL

Not Recruiting

Female: yes
Male: yes

United States;France;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;United Kingdom;Italy

EUCTR2011-000242-38-DE
(EUCTR)

09/01/2013

25/09/2012

A 2 year study to investigate belimumab in membranous nephropathy

BEL114674: A 2 year study of efficacy and safety ofintravenous belimumab versus placebo in subjects withidiopathic membranous nephropathy - GSK1550188 in membranous nephropathy

Idiopathic Membranous Nephropathy (IMN)
MedDRA version: 16.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: BENLYSTA ®
Product Name: BENLYSTA ®
Product Code: GSK1550188 (Belimumab)
INN or Proposed INN: BELIMUMAB

GlaxoSmithKline Research & Development Ltd

NULL

Not Recruiting

Female: yes
Male: yes

France;United States;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;Italy;United Kingdom

EUCTR2011-000242-38-ES
(EUCTR)

20/12/2012

22/10/2012

A 2 year study to investigate belimumab in membranous nephropathy

A 2 year study of efficacy and safety ofintravenous belimumab versus placebo in subjects withidiopathic membranous nephropathy - GSK1550188 in membranous nephropathy

Idiopathic Membranous Nephropathy (IMN)
MedDRA version: 14.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: BENLYSTA ®
Product Name: BENLYSTA ®
Product Code: GSK1550188 (Belimumab)
INN or Proposed INN: BELIMUMAB

GlaxoSmithKline, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

United States;France;Czech Republic;Canada;Spain;Netherlands;Germany;United Kingdom;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-000242-38-IT
(EUCTR)

22/11/2012

11/12/2012

A 2 year study to investigate belimumab in membranous nephropathy

A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy

Trade Name: BENLYSTA
INN or Proposed INN: BELIMUMAB

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.

NULL

Not Recruiting

Female: yes
Male: yes

United States;Czech Republic;Canada;Spain;Germany;United Kingdom;Italy

EUCTR2011-000242-38-GB
(EUCTR)

01/11/2012

03/10/2012

A 2 year study to investigate belimumab in membranous nephropathy

BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - GSK1550188 in membranous nephropathy

Idiopathic Membranous Nephropathy (IMN)
MedDRA version: 15.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

GlaxoSmithKline Research & Development Ltd

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;Italy;United Kingdom

EUCTR2012-000385-38-GB
(EUCTR)

18/05/2012

02/04/2012

A study to investigate belimumab in IMGN

BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy

Idiopathic Membranous Glomerulonephropathy (IMGN)
MedDRA version: 16.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

GlaxoSmithKline Research and Development Ltd

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom